SHLTN.SW up 7.27% to CHF1.18 on 02 Jan 2026 after hours: high-volume top gainer
SHLTN.SW stock rose 7.27% to CHF1.18 after hours on 02 Jan 2026, driven by a 143,309-share session that outpaced the 18,897 average volume and made SHL Telemedicine Ltd. one of the top gainers on the SIX in Switzerland. The move follows a recent run above the 50-day average of CHF1.07 and comes as investors reassess product collaborations, cash position and near-term revenue visibility in the Healthcare information services industry.
Market action after hours
SHLTN.SW closed the regular session at CHF1.10 and traded to CHF1.18 after hours on 02 Jan 2026, a 7.27% rise on volume of 143,309 versus an average 18,897, giving a relative volume of 7.58 and signalling above-normal interest in the SIX-listed stock.
What moved the stock
The after-hours lift came with no single regulatory filing; market participants cited re-rating hopes linked to SHL Telemedicine Ltd.’s SmartHeart device collaborations and improved cash per share of CHF0.81, which supports near-term operations while revenue cadence is reassessed source.
Fundamentals snapshot
At CHF1.18, SHL Telemedicine Ltd. shows EPS -0.76 and a negative PE of -1.55, market cap CHF19,341,353.00, price-to-sales 0.43, and price-to-book 0.63, indicating a valuation discount versus Healthcare peer PB average of 4.39 and sector 3-month performance of -2.72%.
Technical and volume read
Technicals show RSI 53.40 and Bollinger Bands at 1.28/1.05/0.82 with ATR 0.15; the stock is above its 50-day average CHF1.07 but below the 200-day CHF1.56, while on-balance volume turned positive with a one-day surge, consistent with the top-gainer status.
Meyka grade and valuation view
Meyka AI rates SHLTN.SW with a score out of 100: Score 65.75 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus and is informational only and not financial advice.
Analyst scenarios and realistic price targets
Scenario-based targets: a constructive target CHF1.50 (about 27.12% upside) assuming renewed subscriber growth and margin recovery, and a conservative target CHF0.90 (about -23.73% downside) if revenue momentum weakens; these reflect the year high CHF2.87 and year low CHF0.66 range.
Final Thoughts
Key takeaways: SHLTN.SW stock traded as a top gainer on 02 Jan 2026 after hours, up 7.27% to CHF1.18 on unusually high volume that outstripped the 50-day average. Fundamentals show a mixed picture — negative EPS -0.76, negative PE -1.55, modest cash per share CHF0.81 and low price-to-book 0.63 versus Healthcare peers, which underpins both the risk and the potential rerating case. Meyka AI’s forecast model projects a quarterly price of CHF1.34 and a yearly price of CHF1.11; the quarterly projection implies an upside of 13.56% versus the current CHF1.18 while the yearly projection implies a -5.95% downside. Forecasts are model-based projections and not guarantees. Given the elevated intraday volume, short-term momentum may persist, but investors should weigh liquidity, operating cash flow trends and upcoming earnings dates before repositioning in the SIX-listed SHL Telemedicine Ltd.
FAQs
The after-hours rise to CHF1.18 followed heavy trading of 143,309 shares and investor interest tied to device collaborations and improved cash per share; there was no single public regulatory event reported.
Key metrics at CHF1.18 include EPS -0.76, PE -1.55, price-to-sales 0.43 and price-to-book 0.63, showing a valuation discount versus Healthcare peers and reflecting negative earnings.
Meyka AI gives SHLTN.SW a score of 65.75 (Grade B) with a HOLD suggestion; this factors benchmark and sector comparisons, financial growth, key metrics and analyst signals and is for informational use only.
Scenario targets: constructive CHF1.50 and conservative CHF0.90. Meyka AI’s model projects CHF1.34 quarterly (implied +13.56% vs CHF1.18) and CHF1.11 yearly; forecasts are model-based, not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
